(HealthDay)—Fragmin (dalteparin sodium) injection has been granted the first approval for subcutaneous use in preventing recurrence of symptomatic venous thromboembolism (VTE) in children aged 1 month ...

The drug was initially approved by the FDA in 1994 for adults and is a type of heparin. The US Food and Drug Administration has approved Pfizer’s Fragmin (dalteparin sodium) injection to reduce the ...

Pfizer won the backing of a US Food and Drug Administration advisory panel yesterday to extend the use of its anti-clotting drug Fragmin to include the prevention of venous thromboembolism (VTE) in ...

FDA Approves Pfizer's and Eisai's FRAGMIN(R) as First Low-Molecular-Weight Heparin for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients with Cancer WOODCLIFF LAKE, N.J. and NEW ...

The FDA has approved Fragmin, a low molecular weight heparin, for the treatment of symptomatic venous thromboembolism to reduce the recurrence of VTE in pediatric patients 1 month of age and older.

The US Food and Drug Administration (FDA) approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism (VTE) in paediatric ...